News

Enlarge image

BusinessFrance

Sanofi expands in Asia

02.04.2013 - Sanofi will expand its current 4% market stake in Vietnam. Between now and 2015, the French drug major will invest US$75m in a production plant.

The plant, which will be operative by 2015, is designed to meet the raising demand for pharmaceuticals in fast-growing Asian populations such as China, Indonesia and Vietnam. It will have an initial capacity of 90 million units per year, which may be later extended to 150 million units, according to the company.

Sanofi currently runs two plants in Ho Chi Minh City at full capacity, according to Sanofi CEO Chris Viehbacher. “Asia continues to grow and it seems to be less affected by the European economic difficulty,” said the company's head. The rise of income and urbanisation in the region will give people more access to health care. Currently sales from Sanofi’s Vietnamese plants are growing 25% annually, creating more than US$128m annually in Vietnam alone. The company, which exports just 20% of the drugs manufactured in the country, will now expand its production capacity to create an export platform for the Southeast Asian region.

In 2012 Sanofi delivered almost one third of its US$35bn sales in emerging markets, US$4,9bn of that with diabetes drugs alone, where the French are world market leader. Asian countries contribute to more than 60% of the world’s diabetic population and their prevalence of diabetes is increasing. Asians have a strong ethnic and genetic predisposition for diabetes and have lower thresholds for the environmental risk factors. As a result, they develop diabetes at a younger age and at a lower body mass index and waist circumference when compared with the Western population.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/sanofi-expands-in-asia.html

Industry reportGermany

27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).

Clinical ResearchFrancePortugal

21.04.2016 An expert panel’s final report on the fatal drug trial earlier this year in France states that the death of one of the participants was most likely caused by the drug’s toxicity and not by any violation of the rules.

Immuno-oncologyNetherlandsBelgium

21.04.2016 For up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive effects of T-cells.

RegulatorySwitzerlandEU

20.04.2016 The US government is forking out up to US$100m to get Basilea Pharmaceutica’s broad-spectrum antibiotic ceftobiprole on the US market. In the EU, ceftobiprole is already available.

Immuno-oncologyUK

19.04.2016 British drug developer Heptares Therapeutics and mAb maker Kymab Ltd have partnered up in yet another immuno-oncology collaboration. The companies plan to discover antibody meds targeting a superfamily of receptors.

FinancingSwitzerlandFranceEUGermanyDenmark

15.04.2016 Not every company is put off by the current stock market climate. Swiss biopharma company GeNeuro has gone public at Euronext Paris, raising €33m in the process. Others, meanwhile, have to find different ways to raise money.

Event ReviewSwitzerlandBelgiumEU

13.04.2016 Despite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased by 5.1% to CHF5,133m and 400 additional people found jobs in the sector. As usual, the new numbers were presented at the annual Swiss Biotech Day – which set new records as well.

FinancingGermanyNetherlandsEU

12.04.2016 German-Dutch life science investment specialist Forbion Capital Partners has raised more than €180m for its venture capital fund Forbion Capital Fund III. Once more the money will primarily go to European start-ups.

Event ReviewGermanyEU

08.04.2016 Do you win by being innovative?, was the question asked at this year’s DIA Euromeeting in Hamburg. In a relaxed and cooperative atmosphere, regulators, physicians and patients had ample opportunity to interact with the healthcare industry.

M&AIrelandEU

07.04.2016 Pfizer and Allergan have called off their merger, cancelling plans to relocate the US pharma giant to Ireland to avoid US taxation. The US government has put a spoke in Pfizer’s wheels - an unfair move, Allergan says.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

München

BioVaria 2016

Berlin (GER)

XIV. BIONNALE 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • THERAMETRICS (CH)0.03 CHF50.00%
  • PLETHORA (UK)3.38 GBP12.67%

FLOP

  • OXFORD BIOMEDICA (UK)5.52 GBP-8.76%
  • IXICO (UK)39.00 GBP-4.88%
  • BIONOR PHARMA (N)0.85 NOK-4.49%

TOP

  • AB SCIENCE (F)19.21 EUR71.5%
  • SYNAIRGEN (UK)36.25 GBP48.0%
  • BIOFRONTERA (D)3.14 EUR38.3%

FLOP

  • EVOLVA (CH)0.68 CHF-26.1%
  • SERODUS (N)1.70 NOK-26.1%
  • THERAMETRICS (CH)0.03 CHF-25.0%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)31.40 SEK2065.5%
  • NICOX (F)8.73 EUR352.3%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)6.00 SEK-88.2%
  • BB BIOTECH (D)47.86 EUR-81.9%
  • BIOTEST (D)17.00 EUR-77.0%

No liability assumed, Date: 28.04.2016